• Completed initial investment in EW-001 CAR-T therapy
• Secured rights to develop EW-001 outside Greater China
• Advanced Australian manufacturing and US FDA engagement
• A$2.5 million placement completed to fund operations
• Enhanced AI capabilities with Oktopi collaboration

Adalta Ltd has successfully completed its initial investment in EW-001, a first-in-class CAR-T cell therapy for advanced mesothelioma, securing rights to develop it for markets outside Greater China. The company has advanced Australian manufacturing and is preparing for a pre-IND meeting with the US FDA. A$2.5 million was raised to fund operations, and AI capabilities were enhanced through a collaboration with Oktopi. The quarter also saw the world's first approval of a solid-tumour CAR-T therapy in China, validating AdAlta's strategy.

Adalta Ltd is focused on building Australian manufacturing and engaging with the US FDA to unlock near-term value for EW-001. The company is also exploring opportunities to monetize its fibrosis asset AD-214 and its anti-malarial i-body® program WD-34.